EPSOLAY (benzoyl peroxide) by Mayne Pharma is 12. First approved in 2022.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
EPSOLAY is a topical benzoyl peroxide cream approved in April 2022 for the treatment of rosacea. Benzoyl peroxide works as an oxidizing agent with bactericidal and keratolytic properties, though its exact mechanism in rosacea remains unclear. The drug is absorbed by the skin and metabolized to benzoic acid, which is eliminated renally.
Early-stage product in peak lifecycle phase with minimal Part D penetration (803 claims in 2023), suggesting untapped market potential for commercial expansion teams.
12.1 Mechanism of Action Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects but the precise mechanism of action in the treatment of rosacea is unknown. 12.2 Pharmacodynamics The pharmacodynamics of EPSOLAY in the treatment of rosacea are unknown. 12.3 Pharmacokinetics…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
"A Comparative Clinical Evaluation of the Efficacy of Topical Adapalene, Benzoyl Peroxide Gel, Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, and Their Fixed Combination in Mild to Moderate Acne Vulgaris Patients."
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars
Worked on EPSOLAY at Mayne Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moEPSOLAY offers career opportunities in commercial execution and market development for a novel rosacea treatment with minimal current market penetration and zero linked job postings at present. The early-stage peak lifecycle and extended patent protection create sustained demand for brand-building roles, though limited clinical activity reduces medical affairs opportunities.